康方生物三抗登场

动脉网
Mar 11

近日,康方生物宣布其全球首创的ILT2/ILT4/CSF1R三特异性抗体新药AK150获NMPA临床试验默示许可,用于治疗晚期恶性实体瘤,这也是康方生物首个进入临床阶段的三抗新药。ILT2、ILT4和CSF1R在多种实体瘤中高表达,当前单、双靶点药物难以打破肿瘤免疫抑制网络,多特异性抗体有望破解难题。AK150可协同靶向三个靶点,多角度解除免疫抑制,临床前动物模型显示其有肿瘤抑制作用。康方生物是...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10